12.25
-0.61 (-4.74%)
| Penutupan Terdahulu | 12.86 |
| Buka | 12.81 |
| Jumlah Dagangan | 1,711,475 |
| Purata Dagangan (3B) | 1,282,919 |
| Modal Pasaran | 1,027,055,872 |
| Harga / Jualan (P/S) | 126.01 |
| Harga / Buku (P/B) | 4.51 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Aug 2026 |
| Margin Keuntungan | -261.91% |
| Margin Operasi (TTM) | -199.72% |
| EPS Cair (TTM) | -2.42 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 109.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 8.07% |
| Nisbah Semasa (MRQ) | 7.85 |
| Aliran Tunai Operasi (OCF TTM) | -148.18 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -82.41 M |
| Pulangan Atas Aset (ROA TTM) | -29.16% |
| Pulangan Atas Ekuiti (ROE TTM) | -53.54% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | EyePoint, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.83 |
|
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 3.46% |
| % Dimiliki oleh Institusi | 109.22% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |